Related Experiment Video
Updated: Feb 17, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma
Objective:
This study aimed to investigate the role of long non-coding RNA MEG3 (lncRNA MEG3) in osteosarcoma (OS) and further explore the underlying molecular mechanism.
Materials And Methods:
The expression profiles of MEG3 in OS cell lines and normal osteoblast cell line were detected by qRT-PCR. MEG3 was over-expressed in OS cell line by using LV-MEG3. MTT and colony-formation assays were applied for cell proliferation analysis. Cell migration assay was applied to investigate the cell migration ability. In addition, the expression levels of cell growth and metastasis related factors (Notch1, Hes1, TGF-β, N-cadheren and E-cadheren) were determined to illustrate the mechanisms.
Results:
We found that compared with normal osteoblast hFOB1.19 cell line, MEG3 was significantly down-regulated in MG63 and U2OS cell lines, particularly in MG-63 cells. MEG3 was significantly up-regulated in MG63 cells by LV-MEG3. Cell proliferation and migration ability were obviously repressed by MEG3 over-expression. In addition, MEG3 over-expression markedly inhibited Notch1, Hes1,TGF-β and N-cadheren expression, and the expression level of E-cadheren was improved.
Conclusions:
These results indicated that MEG3 could prevent cell growth and metastasis of OS by repressing Notch and TGF-β signaling pathway, thus providing a potential therapeutic target for OS treatment (Tab. 1, Fig. 4, Ref. 30).
Insights
Long non-coding RNA MEG3 (lncRNA MEG3) is downregulated in osteosarcoma (OS). Overexpressing MEG3 inhibits OS cell proliferation and metastasis by suppressing Notch and TGF-β signaling pathways.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Osteosarcoma (OS) is a primary bone malignancy with significant metastatic potential.
- Long non-coding RNAs (lncRNAs) play crucial roles in various cellular processes, including cancer development.
- The specific role of lncRNA MEG3 in OS pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the role of lncRNA MEG3 in osteosarcoma.
- To explore the underlying molecular mechanisms by which MEG3 influences OS cell behavior.
- To assess the therapeutic potential of MEG3 in OS treatment.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to determine MEG3 expression levels in OS cell lines and normal osteoblasts.
- Lentiviral vector (LV-MEG3) mediated overexpression of MEG3 in OS cells.
- MTT and colony-formation assays to evaluate cell proliferation.
- Cell migration assays to assess metastatic potential.
- Western blot analysis to determine the expression of key signaling molecules (Notch1, Hes1, TGF-β, N-cadherin, E-cadherin).
Main Results:
- MEG3 expression was significantly downregulated in OS cell lines (MG63, U2OS) compared to normal osteoblasts (hFOB1.19).
- Overexpression of MEG3 in MG63 cells via LV-MEG3 significantly inhibited cell proliferation and migration.
- MEG3 overexpression markedly suppressed the expression of Notch1, Hes1, TGF-β, and N-cadherin, while increasing E-cadherin expression.
Conclusions:
- lncRNA MEG3 acts as a tumor suppressor in osteosarcoma.
- MEG3 inhibits OS cell growth and metastasis by repressing the Notch and TGF-β signaling pathways.
- MEG3 represents a potential therapeutic target for osteosarcoma treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
lncRNA - Long Non-coding RNAs
Experimental RNAi

